Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifaximin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Placebo pills |
| 2 | ACTIVE_COMPARATOR | Rifaximin |
| Name | Type | Description |
|---|---|---|
| Placebo Comparator | DRUG | Matching oral placebo pills to be taken twice daily for a total of 8 weeks |
| Rifaximin | DRUG | Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks |
Inclusion Criteria: * Male or female subjects, 18 to 80 years of age, inclusive, that can themselves provide written, informed consent and authorization of use of protected health information prior to any study-related procedures and who are, in the opinion of the investigator(s), likely to comply ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Rifaximin is an investigational small molecule being studied for the treatment of Crohn's Disease, a type of inflammatory bowel disease. It is being evaluated for its ability to induce clinical response in patients with this condition. The drug is currently in Phase 2 clinical development for this indication.
Rifaximin is a small molecule antibiotic that works by inhibiting bacterial RNA synthesis. It targets the bacterial DNA-dependent RNA polymerase, thereby reducing intestinal bacterial overgrowth and inflammation. This mechanism is thought to contribute to its potential therapeutic effect in Crohn's Disease.
Rifaximin is being developed by Bausch + Lomb Corporation, a company traded on the New York Stock Exchange under the ticker symbol BLCO. The company is conducting clinical research to evaluate the drug's safety and efficacy for the treatment of Crohn's Disease.
Rifaximin is in Phase 2 clinical development for Crohn's Disease. It is an investigational drug, meaning it has not been approved by regulatory authorities for this use. The drug is being studied in a clinical trial to assess its ability to induce clinical response in patients.
Rifaximin has been studied in one completed Phase 2 clinical trial with the identifier NCT00603616, titled 'Induction of Clinical Response Using Rifaximin in Crohn's Disease.' This randomized, double-blind, placebo-controlled trial enrolled 36 participants in the United States and included biomarker-selected patients.
Rifaximin is the generic name of the drug also known as Xifaxan. The drug is being investigated for Crohn's Disease, and it is important to note that while Xifaxan is an approved brand name for rifaximin in other indications, its use in Crohn's Disease remains investigational and is not yet approved.